LOGIN  |  REGISTER
Amneal Pharmaceuticals
Cue Biopharma

The Ensign Group Increases Quarterly Dividend to $0.0575 Per Share

December 16, 2022 | Last Trade: US$127.98 0.20 -0.16

SAN JUAN CAPISTRANO, California, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0575 per share of Ensign common stock, payable on or before January 31, 2023, to shareholders of record as of December 31, 2022. “We are pleased to announce our twentieth consecutive annual dividend increase, which reflects our strong market position and continued commitment to return value to our shareholders,” commented Barry Port, Ensign's Chief Executive Officer. “We look forward to continued growth and are optimistic about our long-term prospects,” he added.

Ensign has been a dividend-paying company since 2002.

About Ensign

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 271 healthcare facilities, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.


Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page